Erythropoietin (EPO) Stimulating Agents: Impact of Proposed CMS Guidelines - A Survey of Fifty-Three US-Based Oncologists
Posted on: Friday, 7 March 2008, 12:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c85056) has announced the addition of Erythropoietin (EPO) Stimulating Agents: Impact of Proposed CMS Guidelines - A Survey of Fifty-Three US-Based Oncologists (Survey) to their offering.
Study Description
Topic: Centers for Medicare & Medicaid Services (CMS) May 14th proposal regarding usage of erythropoiesis-stimulating agents (ESAs)
Respondent Type: Physicians
Specialty: Oncology
Region: United States only
Methodology: Online survey, self-administered via a Panel Intelligence website
- Duration: 20 minutes
- Size: 53 respondents
- Fielding dates: June 7 through June 10, 2007
Objectives: To quantify the potential impact of the CMS proposal on ESA usage by surveying a set of oncologists with large practices.
- Determine current practices in ESA treatment by patient type and cancer type.
- Estimate potential impact overall and by patient type and cancer type.
- Gauge physician reactions to proposed guidelines.
- Anticipate impact on treatment duration and baseline Hg levels.
- Understand importance and potential benefits of ESA usage with regard to quality of life.
Inclusion Criteria and Respondent Demographics:
- Board-certified or eligible oncologist
- In practice between 2 and 30 years post-residency
- Spends at least 75% of professional time in clinical practice
- Manages at least 200 oncology patients on average per month
- Currently uses ESAs to treat oncology patients
For more information visit http://www.researchandmarkets.com/reports/c85056.
Source: Business Wire
Related Articles
- iGPS Plastic Pallet Survey Reveals Potential Warehouse Fire Hazards Remain
- For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
- Gravity Survey Enhances Potential of Nuinsco's Diabase Uranium Project
- Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated By More Than 170 Abstracts at ASCO Annual Meeting
- Onmark Announces Results of Second Annual Office-Based Oncology Business Benchmarking Survey
- Results of Onmark's First Annual Office-Based Oncology Business Benchmarking Survey Published in Journal of Oncology Practice
- Millennium Biotechnologies, Inc. And AlphaMedica Inc. Partner and Announce Oncology Nurses Society Survey Results
- Oncology World Congress Survey Finds Wide Gap Between Urban and Rural Oncologists in Resource and Information Access
- Doctors Cautious on COX-2 Drugs in Wake of Vioxx Withdrawal, Pri-Med Survey Finds; Potential ``Class Effect'' a Concern When Treating Patients With Heart Issues
 |
 |
User Comments (0)
RSS Feeds